Recent trends in the gene therapy of β-thalassemia
Open Access
- 1 February 2015
- journal article
- review article
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. 6, 69-85
Abstract
The β-thalassemias are a group of hereditary hematological diseases caused by over 300 mutations of the adult β-globin gene. Together with sickle cell anemia, thalassemia syndromes are among the most impactful diseases in developing countries, in which the lack of genetic counseling and prenatal diagnosis have contributed to the maintenance of a very high frequency of these genetic diseases in the population. Gene therapy for β-thalassemia has recently seen steadily accelerating progress and has reached a crossroads in its development. Presently, data from past and ongoing clinical trials guide the design of further clinical and preclinical studies based on gene augmentation, while fundamental insights into globin switching and new technology developments have inspired the investigation of novel gene-therapy approaches. Moreover, human erythropoietic stem cells from β-thalassemia patients have been the cellular targets of choice to date whereas future gene-therapy studies might increasingly draw on induced pluripotent stem cells. Herein, we summarize the most significant developments in β-thalassemia gene therapy over the last decade, with a strong emphasis on the most recent findings, for β-thalassemia model systems; for β-, γ-, and anti-sickling β-globin gene addition and combinatorial approaches including the latest results of clinical trials; and for novel approaches, such as transgene-mediated activation of γ-globin and genome editing using designer nucleases.Keywords
This publication has 156 references indexed in Scilit:
- Controlling Long-Range Genomic Interactions at a Native Locus by Targeted Tethering of a Looping FactorCell, 2012
- A combined approach for β-thalassemia based on gene therapy-mediated adult hemoglobin (HbA) production and fetal hemoglobin (HbF) inductionAnnals of Hematology, 2012
- Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cellsNature Biotechnology, 2011
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Analysis of alpha hemoglobin stabilizing protein overexpression in murine β‐thalassemiaAmerican Journal of Hematology, 2010
- Correction of β‐thalassemia major by gene transfer in haematopoietic progenitors of pediatric patientsEMBO Molecular Medicine, 2010
- Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleasesNature Biotechnology, 2009
- Correction of Murine Sickle Cell Disease Using γ-Globin Lentiviral Vectors to Mediate High-level Expression of Fetal HemoglobinMolecular Therapy, 2009
- Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleasesNature Biotechnology, 2008
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006